AltMountain

Paradigm Biocapital Advisors LP

New York, NY · CRD 312544
Hedge fund manager

Paradigm Biocapital Advisors LP is an SEC-registered investment adviser based in New York, NY that reports managing 2 hedge funds on Form ADV. It reports $4.5 billion in regulatory assets under management. Its private funds, of all types, hold $4.1 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +31.4% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +81.1% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$4.5 billionForm ADV Item 5.F
Gross assets of private funds
$4.1 billionAll private fund types, Form ADV
Hedge funds managed
22 private funds in total
Employees
11Form ADV Item 5.A
Registration
SEC-registered adviserCRD 312544
Latest Form ADV
08/27/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+31.4%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+81.1%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$5.3 billion28 positions, 2026-06-30
$84$133$181Q3 2024Q1 2025Q3 2025Q1 202613F est. $181S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+15.8%+14.8%
Q1 2026+13.5%-4.6%
Q4 2025+24.5%+2.4%
Q3 2025+31.2%+7.8%
Q2 2025-0.3%+10.4%
Q1 2025-19.3%-4.5%
Q4 2024-10.3%+2.1%
Q3 2024+16.8%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 30 share positions ($5,028,958,519) reported by Paradigm Biocapital Advisors LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Revolution Medicines Inc25.38%
  • Genmab A/s10.03%
  • Edgewise Therapeutics Inc8.70%
  • Spyre Therapeutics Inc7.89%
  • Insmed Inc6.12%
  • MBX Biosciences Inc4.40%
  • Oruka Therapeutics Inc4.13%
  • Belite Bio Inc3.86%
  • Tarsus Pharmaceuticals Inc3.60%
  • Tango Therapeutics Inc3.45%
StockValue% of 13F portfolioSharesShares vs prior quarter
Revolution Medicines Inc$1,276,578,23925.38%6,219,323-2.23%
Genmab A/s$504,318,63910.03%14,136,472+7.64%
Edgewise Therapeutics Inc$437,613,7998.70%10,778,665+5.51%
Spyre Therapeutics Inc$396,846,7747.89%4,457,450+16.06%
Insmed Inc$307,718,8156.12%2,695,977+103.32%
MBX Biosciences Inc$221,166,5194.40%3,772,885+50.43%
Oruka Therapeutics Inc$207,684,1984.13%2,493,507+16.27%
Belite Bio Inc$193,955,3283.86%1,142,123-7.36%
Tarsus Pharmaceuticals Inc$180,911,0893.60%2,301,375-17.09%
Tango Therapeutics Inc$173,690,5733.45%6,961,546+9.50%
Viridian Therapeutics Inc$170,025,4663.38%8,257,672+22.81%
Bridgebio Pharma Inc$154,488,5303.07%2,347,850New
Vaxcyte Inc$121,928,2792.42%2,142,852+0.70%
Erasca Inc$117,254,4482.33%7,998,257-16.25%
Jade Biosciences Inc$85,048,4151.69%6,053,268+111.84%
Tyra Biosciences Inc$76,771,5731.53%3,510,360+91.97%
Olema Pharmaceuticals Inc$75,345,7771.50%8,720,576+0.58%
Obsidian Therapeutics Inc$57,051,0881.13%4,155,214New
Structure Therapeutics Inc$40,625,9530.81%1,299,199New
Achieve Life Science Inc$40,060,5150.80%4,951,856Unchanged
Veradermics Inc$37,588,5740.75%310,060New
Assembly Biosciences Inc$36,497,5410.73%1,553,748Unchanged
Oric Pharmaceuticals Inc$20,282,7080.40%1,505,769New
Korsana Biosciences Inc$19,645,2480.39%613,914New
Editas Medicine Inc$19,468,1100.39%7,575,140+35.59%
Hemab Therapeutics Hldgs Inc$19,409,0610.39%629,347New
Vor Biopharma Inc$16,973,0910.34%889,575-49.17%
Kardigan Inc$13,275,0000.26%900,000Unchanged
Tcgx Acquisition Corp$3,753,0000.07%300,000New
Inventiva SA$2,982,1690.06%808,176-79.80%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 8 new positions, 6 sold out, 13 increased, 6 reduced and 3 unchanged.

Number of positions (a count, not dollars)

  • New positions8
  • Increased13
  • Unchanged3
  • Reduced6
  • Sold out6

New positions

StockValueShares
Bridgebio Pharma Inc$154,488,5302,347,850
Obsidian Therapeutics Inc$57,051,0884,155,214
Structure Therapeutics Inc$40,625,9531,299,199
Veradermics Inc$37,588,574310,060
Oric Pharmaceuticals Inc$20,282,7081,505,769
Korsana Biosciences Inc$19,645,248613,914
Hemab Therapeutics Hldgs Inc$19,409,061629,347
Tcgx Acquisition Corp$3,753,000300,000

Sold out

StockValue at Jun 30, 2026Shares held then
Nuvalent Inc$731,667,4765,924,433
Apogee Therapeutics Inc$209,233,5811,576,385
Alnylam Pharmaceuticals Inc$144,494,400480,000
Eyepoint Inc$41,332,6772,890,397
Maplight Therapeutics Inc$24,580,936685,852
Lexeo Therapeutics Inc$19,436,4034,175,382

Largest increases

StockChange in sharesChangeValue nowShares now
Insmed Inc+1,370,000+103.32%$307,718,8152,695,977
MBX Biosciences Inc+1,264,870+50.43%$221,166,5193,772,885
Spyre Therapeutics Inc+616,672+16.06%$396,846,7744,457,450
Jade Biosciences Inc+3,195,863+111.84%$85,048,4156,053,268
Tyra Biosciences Inc+1,681,753+91.97%$76,771,5733,510,360
Genmab A/s+1,003,341+7.64%$504,318,63914,136,472
Viridian Therapeutics Inc+1,533,884+22.81%$170,025,4668,257,672
Oruka Therapeutics Inc+348,981+16.27%$207,684,1982,493,507
Edgewise Therapeutics Inc+563,210+5.51%$437,613,79910,778,665
Tango Therapeutics Inc+604,023+9.50%$173,690,5736,961,546
Editas Medicine Inc+1,988,515+35.59%$19,468,1107,575,140
Vaxcyte Inc+15,000+0.70%$121,928,2792,142,852
Olema Pharmaceuticals Inc+50,000+0.58%$75,345,7778,720,576

Largest reductions

StockChange in sharesChangeValue nowShares now
Tarsus Pharmaceuticals Inc-474,274-17.09%$180,911,0892,301,375
Revolution Medicines Inc-142,000-2.23%$1,276,578,2396,219,323
Erasca Inc-1,551,743-16.25%$117,254,4487,998,257
Vor Biopharma Inc-860,425-49.17%$16,973,091889,575
Belite Bio Inc-90,754-7.36%$193,955,3281,142,123
Inventiva SA-3,191,824-79.80%$2,982,169808,176

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Jade Biosciences, Inc.13G amendment9.5%6,053,268Nov 16, 2026SEC.gov ↗
Viridian Therapeutics, Inc.13G amendment7.3%8,257,672Nov 16, 2026SEC.gov ↗
Lexeo Therapeutics, Inc.13G amendment0%0Nov 16, 2026SEC.gov ↗
Nuvalent, Inc.13G amendment0%0Nov 16, 2026SEC.gov ↗
Tarsus Pharmaceuticals, Inc.13G amendment4.7%2,301,375Nov 16, 2026SEC.gov ↗
MBX Biosciences, Inc.13G amendment7.8%3,772,885Nov 16, 2026SEC.gov ↗
Obsidian Therapeutics, Inc.13G6.6%4,101,576Oct 5, 2026SEC.gov ↗
Spyre Therapeutics, Inc.13G5.1%4,457,450Oct 1, 2026SEC.gov ↗
Tyra Biosciences, Inc.13G5.8%3,473,453Sep 17, 2026SEC.gov ↗
Arcellx, Inc.13G amendment0%0Aug 14, 2026SEC.gov ↗
Assembly Biosciences, Inc.13G amendment7.8%1,553,748Aug 14, 2026SEC.gov ↗
Edgewise Therapeutics, Inc.13G amendment9.5%10,215,455Aug 14, 2026SEC.gov ↗
Maze Therapeutics, Inc.13G amendment0%0Aug 14, 2026SEC.gov ↗
EyePoint, Inc.13G amendment3.8%3,142,437May 15, 2026SEC.gov ↗
UroGen Pharma Ltd.13G amendment3.5%1,703,949May 15, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 14, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 24 companies. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (6)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (1)

Fund
Gross assets
Minimum
Owners
Adviser
Paradigm Biocapital International Fund LTD.
Cayman IslandsHedge fund
Gross assets$2.0B
Minimum$5.0M
Owners126
AdviserParadigm Biocapital Advisors LP

As reported in the adviser's Form ADV filed Sep 20, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​​​⁠